Portfolio Finder

WISE Srl is a Milan and Berlin-based company developing genuinely novel and minimally-invasive implantable leads for Neuromodulation and Neuromonitoring: highly conformable, stretchable, unbreakable and cheaper to produce.

WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is based on the fact that many cancer cells predominantly produce their energy through a high rate of glycolysis followed by lactic acid fermentation even in the presence of abundant oxygen. Using this mechanism for the treatment of cancer turns out to be very difficult, as interventions targeted at the sugar metabolism also cause harm to healthy cells. The approach WMT is using offers an improved therapeutic window as opposed to classical cancer medicines.

Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for R&D and diagnostics.